AGREEMENT

Exhibit 10.4

AGREEMENT

This Agreement (“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between:

Tel Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Xxxxxxxx, Xxxxxx, 00000, represented by its authorized representatives (“THM”); and

Xxxx. Xxxx Xxxxxx, ID no. 000000000 of Ramat Gan, Israel (“Xxxx. Xxxxxx”); and

Vascular Biogenics Ltd., Company no. 00-000000-0, a private company duly incorporated under the laws of the State of Israel having its registered office at 6 Xxxx Xxxxxxxxx Street, Or Xxxxxx, Xxxxxx, 00000, represented by its authorized representatives (“VBL” or the “Company”).

 

WHEREAS: THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and

 

WHEREAS: THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees;and

 

WHEREAS: Xxxx. Xxxxxx has been an employee of the Hospital and/or the Fund since 1995; and

 

WHEREAS: VBL was established in 1999; and

 

WHEREAS: The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Xxxx. Xxxxxx, and certain other inventors defined herein as Inventors and VBL disagrees, denies and refutes all such claims in their entirety; and

 

WHEREAS: THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder;

 

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties hereby agree and stipulate as follows:

 

1. PREAMBLE AND DEFINITIONS

 

  1.1 The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof.

 

  1.2 The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement.

 

  1.3 In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter:

 

  1.3.1 “Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity.

 

  1.3.2 The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA).

 

  1.3.3 “Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States, Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service xxxx registrations and applications therefore throughout the world; and (vi) all domain names, uniform resource locators, and other names and locators associated with the internet.

 

2

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  1.3.4 The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba.

 

  1.3.5 The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii)any continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon.

 

  1.3.6 The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the Company’s IP.

 

  1.3.7 “Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes, excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate uses; provided however that the Company doesn’t receive any consideration relating thereto;

 

     For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph (a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable.

 

  1.3.8 “License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly.

 

3

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  1.3.9 “License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return for or in connection with the grant of Licences or the grant of an option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments, etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause.

 

  1.3.10 “First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such country has been obtained if such approval is required.

 

2. PARTIES’ DECLARATIONS AND UNDERTAKINGS

 

  2.1 THM undertakes and covenants as follows:

 

  2.1.1 Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right to receive any payment, compensation, funds or securities from Xxxx. Xxxx Xxxxxx and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights, claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s IP now or in the future, (“Released Matters”).

 

4

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

       Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created, conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or contractors on behalf of the Company to the extent they are not listed in Appendix A.

 

  2.1.2 2.1.3 Xxxx Xxxxxx shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties.

 

  2.2 Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received.

 

5

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

3. LICENSE BY THE COMPANY

VBL undertakes that any License granted by it shall be subject to the following terms:

 

  3.1 The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with such terms.

 

  3.2 The License is being granted in a bona fide arms-length commercial transaction.

 

  3.3 Non monetary consideration, if any, shall be valued as set forth in this Agreement.

 

4. CONSIDERATION TO THM

 

  4.1 VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country:

 

  4.1.1 Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”).

 

  4.1.2 Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”).

 

  4.2 The amounts payable to THM under clause 4.1 shall be paid as follows:

 

  4.2.1 Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL receives payment on account of Net Sales.

 

  4.2.2 Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL.

 

6

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  4.3 Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”).

Consideration from Exit Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may pay the Consideration From Exit within 12 months following the closing of the respective Exit Event.

“Exit Event” means any of the following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile or structure of VBL shall not be deemed an Exit Event.

 

  4.4. Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM, provided that such amounts were not received by THM as Royalties under clause 4.1.1. It is hereby clarified that termination of the obligation to pay Consideration From Exit, according to this clause 4.4 which did not exceed NIS 100 million, does not and shall not derogate from Company’s obligation for payments as specified in clauses 4.1.1 and 4.1.2 until an aggregate payment of NIS 100 million has been made (but not by way of payment of Royalties payable under clause 4.1.1).

 

  4.5 All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount applicable to THM in connection with each payment.

 

  4.6 The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report the date of execution of such agreement and the date of the First Commercial Sale according to the agreement.

 

  4.7 In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be.

 

7

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  4.8 The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form reasonably acceptable to THM, signed by the chief financial officer of VBL, specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts payable hereunder; and (c)Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of such Exit will be disclosed orally by the legal counsel of VBL to the head of THM.

 

  4.9 The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices.

 

  4.10 Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of 4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year.

 

8

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  4.11 Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the Company conducted for the development of Products; and (ii) sales and marketing efforts.

 

5. INDEMNITY

 

  5.1 VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM Claim”).

 

  5.2     

 

  5.3 The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion.

 

  5.4 VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product liability and (iii) commercial sales of applicable and relevant Products.

 

6. PATENT RIGHTS

In the event that the Company decides to abandon its patents in all applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM (“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights.

 

9

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4 and that any such agreement shall be subject to any limitations and restrictions imposed by applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period.

 

7. MISCELLANEOUS

 

  7.1 Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel.

 

  7.2 Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication including commercial publicity, without the prior written consent of THM.

 

  7.3 Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party. Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital. In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement.

 

10

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

  7.4 Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid, return receipt requested, if sent by Registered Mail and addressed to the address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof.

 

  7.5 Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem expedient.

 

  7.6 Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties.

 

  7.7 Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations, or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings.

 

  7.8 THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work as medical doctors for Sheba such as Xxxx. Xxxx Charats, Xxxx. Xxxxxxxxx and Xxxx. Xxxxx Xxxxx, shall belong to Sheba.

 

11

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

[Remainder of the Page was left intentionally blank]

 

12

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement.

 

Tel Hashomer - Medical Research,       Vascular Biogenics Ltd.
Infrastructure and Services Ltd.      
By:  

[Illegible]

       By:  

/s/ Xxxx Xxxxxx

/s/ Xxxx Xxxxxx

Xxxx. Xxxx Xxxxxx

        
Approved and Acknowledged        

[Illegible]

The Government of Israel

By the Ministry of Health

        

 

13

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Appendix A

INVENTORS

1. Xxxx. Xxxx Xxxxxx

2. Xxxxxxxxx Xxxxxx

3. Xxxxxx Xxxxx

4. Xxxxxxxx Xxxxxx – up to 2003

5. Xxxxx Xxxx

6. Xxxxxxxxxxx Xxxxxxxx

7. Xxx Xxxxxx

8. Xxxxx Xxxxxxx

 

* detailed list of inventions is provided under Appendix B.

 

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Appendix B’ up to 3 Feb 2013

 

METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

 

ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS

 

Our Ref

    Country    Earliest Priority    Entry
Date		    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

52423

    PCT    19-Oct-2010       12/10/2011       3182.041PC01    Pending   

 

TREATMENT WITH VB-201

 

Our Ref

    Country    Earliest Priority    Entry
Date		    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

[* * *]

                       

50378

    PCT    05-Jan-2010

61/292,226

       05-Jan-2011

IL2011/000012

    Publ. Date: 14-Jul-2011

Publ. #: WO2011/083469

   3182.018PC05    Expired    XXXXX Xxxx; BREITBART

Eyal; XXXXXX Xxxxxx; XXXXX

Xxxx; XXXXX Xxxx

 

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

PAF-LIKE HOMOLOGS AND USES THEREOF

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

44504

    PCT    16-Oct-2007

60/960,846

       05-Oct-2008

IL2008/001315

    Publ. Date: 23-Apr-2009

Publ. #: WO2009/050692

      Expired    XXXXX Xxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    Xxxxxx

NP

    16-Oct-2007

60/960,846

    15-Apr-2010    05-Oct-2008

205144

      3182.019IL01    Aban    XXXXX Xxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    XXX

NP

    16-Oct-2007

60/960,846

    15-Apr-2010    05-Oct-2008

12/738,097

      3182.0190001    Aban    XXXXX Xxxx; BREITBART
Eyal; XXXXXX Xxxxxx

48217

    Europe

NP

    16-Oct-2007

60/960,846

    14-May-2010    05-Oct-2008

08808113.8

      3182.019EP01    Aban    XXXXX Xxxx; BREITBART
Eyal; XXXXXX Xxxxxx

 

IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

 

3

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent Xx.		   XXXX Xxx    Xxxxxx    Xxxxxxxx

00000

    PCT    09-Jul-2004

60/586,219

       10-Jul-2005

IL2005/000735

    Publ. Date: 19-Jan-2006

Publ. #: WO2006/006161

      Expired    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

NP

    09-Jul-2004

60/586,219

    09-Jan-2007    10-Jul-2005    1-Mar-2012

180628

   3182.020IL00    GRANTED    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

DIV

    09-Jul-2004

60/586,219

    17-Mar-2011    10-Jul-2005

211795

         Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

DIV

    09-Jul-2004

60/586,219

    17-Mar-2011    10-Jul-2005

211796

         Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

NP

    09-Jul-2004

60/586,219

    09-Feb-2007    10-Jul-2005

05758938.4

         Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000 Xxx

    Europe

Div

    09-Jul-2004

60/586,219

    Oct 2012    10-Jul-2005      3182.020EP10    Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000 Xxx

    Europe

Div

    09-Jul-2004

60/586,219

    Oct 2012    10-Jul-2005

12179533.0

      3182.020EP20    Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxx Xxxx

XX

    09-Jul-2004

60/586,219

    31-May-2007    10-Jul-2005

07105789.7

         Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

00000

    Xxxxxx

NP

    09-Jul-2004

60/586,219

    09-Jan-2007    10-Jul-2005

2,573,396

         Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

 

4

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxx

NP

    09-Jul-2004

60/586,219

    09-Jan-2007    10-Jul-2005

2007-519983

    24-Jun-2011

4,767,948

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx

DIV

    09-Jul-2004

60/586,219

    21-May-2010    10-Jul-2005

2010-116964

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxxxx xx Xxxxx

NP

    09-Jul-2004

60/586,219

    09-Feb-2007    10-Jul-2005

2007-7003288

    9-Nov-2012

00-0000000

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx

NP

    09-Jul-2004

60/586,219

    28-Feb-2007    10-Jul-2005

200580029218.9

    3-Aug-2011

200580029218.9

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx

DIV

    09-Jul-2004

60/586,219

    11-Feb-2010    10-Jul-2005

201010128184.1

          Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

[* * *]

                        

[* * *]

                        

00000

    Xxxxxxx Federation

NP

    09-Jul-2004

60/586,219

    09-Feb-2007    10-Jul-2005

2007105097

    20-Sep-2010

2399626

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

NP

    09-Jul-2004

60/586,219

    08-Jan-2007    10-Jul-2005

MX/a/2007/000361

    17-Mar-2011

284830

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxxxxx

DIV

    09-Jul-2004

60/586,219

    09-Jan-2007    10-Jul-2005

2007200090

    2007200090

5 Jan 2012

    3182.020AU00    Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

DIV

    09-Jul-2004

60/586,219

    14-Jan-2011    10-Jul-2005

MX/a/2011/000630

    3 Sep 2012

303011

       Granetd    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

 

5

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

33804

    New Zealand

NP

    09-Jul-2004

60/586,219

    09-Feb-2007    10-Jul-2005

553147

    06-Nov-2010

553147

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxx Xxxxxxx

DIV

    09-Jul-2004

60/586,219

    29-Jun-2010    10-Jul-2005

586503

    10 Oct 2011

586503

       Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx Xxxxxx

NP

    09-Jul-2004

60/586,219

       10-Jul-2005

2007/01178

    25-Sep-2008

2007/01178

       Granted    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

 

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

02/23345

    USA

CIP

    17-Nov-2000

60/248,582

       01-May-2002

10/135,447

    27-Jun-2006

7,067,649

       Granted    HARATS Dror; BREITBART
Eyal; XXXXX Xxxx

00000

    XXX

DIV

    17-Nov-2000

60/248,582

    29-Oct-2004    01-May-2002

10/975,619

    25-Aug-2009

7,579,327

       Granted    HARATS Dror; BREITBART
Eyal; XXXXX Xxxx

00000

    XXX

DIV

    17-Nov-2000

60/248,582

    03-Jun-2009    01-May-2002

12/457,200

          Pending    HARATS Dror; BREITBART
Eyal; XXXXX Xxxx

00000

    XXX

DIV

    17-Nov-2000

60/248,582

    27-Apr-2011    01-May-2002

13/094,900

          Pending    HARATS Dror; BREITBART
Eyal; XXXXX Xxxx

00000

    XXX

DIV

    17-Nov-2000

60/248,582

    24-April
2012		    01-May-2002

13/454,171

       3182.0350004    Pending    HARATS Dror; BREITBART
Eyal; XXXXX Xxxx

 

6

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

25974

    PCT    01-May-2002

10/135,447

       30-Apr-2003

IL03/00347

    Publ. Date: 13-Nov-2003

Publ. #: WO03/093409

      Expired    HARATS
Dror

00000

    Xxxxxxxxx

NP

    01-May-2002

10/135,447

    01-Nov-2004    30-Apr-2003

200406381-4

    30-May-2008

107841 [WO 03/093409]

      Granted    HARATS
Dror;
BREITBART
Eyal;
XXXXX
Xxxx

00000

    South Africa

NP

    01-May-2002

10/135,447

    05-Nov-2004    30-Apr-2003

2004/8989

    26-Jul-2006

2004/8989

      Granted    HARATS
Dror;
BREITBART
Eyal;
XXXXX
Xxxx

[* * *]

                       

[* * *]

                       

00000

    Xxxxx

NP

    01-May-2002

10/135,447

    01-Nov-2004    30-Apr-2003

2004-501545

         Abandoned    HARATS
Dror

[* * *]

                       

[* * *]

                       

[* * *]

                       

00000

    Xxxxxx

NP

    01-May-2002

10/135,447

    01-Nov-2004    30-Apr-2003

2,483,996

         Abandoned    HARATS
Dror;
BREITBART
Eyal;
XXXXX
Xxxx

00000

    Mexico

NP

    01-May-2002

10/135,447

    28-Oct-2004    30-Apr-2003

PA/a/2004/010711

         Abandoned    HARATS
Dror;
BREITBART
Eyal;
XXXXX
Xxxx

[* * *]

                       

 

7

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

COMBINED TREATMENT UTILIZING VB-201

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

50379

    PCT    05-Jan-2010

61/292,226

       05-Jan-2011

IL2011/000010

    Publ. Date: 14-Jul-2011

Publ. #: WO2011/083467

      Expired    XXXXX Xxxx; BREITBART
Eyal; XXXXX Xxxx
   US
NP		    05-Jan-2010

61/292,226

    5-July 2012    05-Jan-2011

13/520,713

      3182.0160005    Pending    XXXXX Xxxx; BREITBART
Eyal; XXXXX Xxxx
   EP
NP		    05-Jan-2010

61/292,226

    1-Aug 2012         3182.016EP05    Pending    XXXXX Xxxx; BREITBART
Eyal; XXXXX Xxxx
   JP
NP		    05-Jan-2010

61/292,226

    4-July 2012         3182.016JP05    Pending    XXXXX Xxxx; BREITBART
Eyal; XXXXX Xxxx

 

POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA

 

Our
Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

41795

    PCT    31-Jul-2006

60/834,157

       31-Jul-2007

IL2007/000959

    Publ. Date: 07-Feb-2008

Publ. #: WO/2008/015675

      Expired    XXX Xxxxxx; BREITBART Eyal;
XXXXXX Xxxxxx

00000

    Xxxxx

NP

    31-Jul-2006

60/834,157

    26-Mar-2009    31-Jul-2007

200780035863.0

    8-Aug 2012

ZL20078003 5863.0

   3182.040CN01    Granted    XXX Xxxxxx; BREITBART Eyal;
BANGIO Livnat

 

8

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxx

Div

    31-Jul-2006

60/834,157

    26-June-2012    31-Jul-2007

201210210646.3

       3182.040CN11    Pending    XXX Xxxxxx; BREITBART
Eyal; BANGIO Xxxxxx

00000

    XXX

NP

    31-Jul-2006

60/834,157

    02-Feb-2009    31-Jul-2007

12/309,856

          Abandoned    XXX Xxxxxx; BREITBART
Eyal; BANGIO Xxxxxx

00000

    XXX

DIV

    31-Jul-2006

60/834,157

    20-Jun-2011    31-Jul-2007

13/163,776

          Pending    XXX Xxxxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    Xxxxxx

NP

    31-Jul-2006

60/834,157

    29-Jan-2009    31-Jul-2007

196792

          Pending    XXX Xxxxxx; BREITBART
Eyal; BANGIO Livnat

[* * *]

                        

[* * *]

                        

[* * *]

                        

[* * *]

                        

00000

    Xxxxxxxxx

NP

    31-Jul-2006

60/834,157

    02-Feb-2009    31-Jul-2007

2007280017

    26-July 2012

2007280017

    3182.040AU01    Granted    XXX Xxxxxx; BREITBART Eyal;
XXXXXX Xxxxxx

00000

    Xxxxxxxxx

Div

    31-Jul-2006

60/834,157

    12-July 2012    31-Jul-2007

2012204128

       3182.040AU11    Pending    XXX Xxxxxx; BREITBART Eyal;
XXXXXX Xxxxxx

00000

    Xxxxx

NP

    31-Jul-2006

60/834,157

    02-Feb-2009    31-Jul-2007

2009-522416

          Pending    XXX Xxxxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    Xxxxxxxx of Korea

NP

    31-Jul-2006

60/834,157

    27-Feb-2009    31-Jul-2007

2009-7004288

          Abandoned    XXX Xxxxxx; BREITBART Eyal;
BANGIO Livnat

 

9

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxx

NP

    31-Jul-2006

60/834,157

    29-Jan-2009    31-Jul-2007

MX/a/2009/001157

         Pending    XXX Xxxxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    Xxx Xxxxxxx

NP

    31-Jul-2006

60/834,157

    26-Jan-2009    31-Jul-2007

574410

    9 July 2012

574410

   3182.040NZ01    Granted    XXX Xxxxxx; BREITBART
Eyal; XXXXXX Xxxxxx

00000

    Xxxxx Xxxxxx

NP

    31-Jul-2006

60/834,157

    26-Jan-2009    31-Jul-2007

2009/00581

    31-Mar-2010

2009/00581

      Granted    XXX Xxxxxx; BREITBART
Eyal; BANGIO Livnat

00000

    Xxxxxxxxx

NP

    31-Jul-2006

60/834,157

    30-Jan-2009    31-Jul-2007

200900642-0

    30-Jun-2011

149616[WO2008/015675]

      Granted    XXX Xxxxxx; BREITBART Eyal;
BANGIO Livnat

 

TREATMENT WITH VB-201

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

[* * *]

                       

50377

    PCT    05-Jan-2010

61/292,226

       05-Jan-2011

IL2011/000008

    Publ. Date: 14-Jul-2011

Publ. #: WO2011/083465

      Expired    XXXXX Xxxx; BREITBART
Eyal; XXXXXX Xxxxxx; XXXX
Xxxxxx; XXXXX Xxxx
   US NP    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011      3182.0170005    Pending   
   AU NP    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011      3182.017AU05    Pending   

 

10

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

[* * *]

                        
   CANADA
NP		    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017CA05    Pending   
   China

NP

    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017CN05    Pending   
   HK

NP

    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017HK05    Pending   
   EP NP    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017EP05    Pending   

[* * *]

                        

[* * *]

                        
   Japan

NP

    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017JP05    Pending   
   South Korea

NP

    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017KR05    Pending   
   MX

NP

    05-Jan-2010

61/292,226

    June 2012    05-Jan-2011       3182.017MX05    Pending   

[* * *]

                        

[* * *]

                        

 

11

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

 

METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent Xx.		   XXXX Xxx    Xxxxxx    Xxxxxxxx

00000

    PCT    12-Jan-2010

61/294,158

       12-Jan-2011

IB2011/050137

    Publ. Date: 21-Jul-2011

Publ. #: WO2011/086509

      Expired    BREITBART
Eyal;
BANGIO
Livnat;
XXXX
Xxxxxx
   US NP    12-Jan-2010

61/294,158

    June 2012    12-Jan-2011      3182.0330001    Pending    BREITBART
Eyal;
BANGIO
Livnat;
XXXX
Xxxxxx
   EP NP    12-Jan-2010

61/294,158

    June 2012    12-Jan-2011      3182.033EP01    Pending    BREITBART
Eyal;
BANGIO
Livnat;
XXXX
Xxxxxx

[* * *]

                       
   JP NP    12-Jan-2010

61/294,158

    June 2012    12-Jan-2011      3182.033JP01    Pending    BREITBART
Eyal;
BANGIO
Livnat;
XXXX
Xxxxxx

[* * *]

                       

 

12

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

 

METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

01/22753

    PCT    24-Nov-2000

60/252,574

       22-Nov-2001

IL01/01080

    Publ. Date: 30-May-2002

Publ. #: WO02/41827

      Expired    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

26035

    Europe

NP

    22-Nov-2000

60/252,574

    15-May-2003    22-Nov-2001

01997274.4

         Pending    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

52529

    EP Div    22-Nov-2000

60/252,574

    17-Nov 2011    22-Nov-2001

11189562.9

      3182.021EP11    Pending    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

27265

    Hong Kong

NP

    24-Nov-2000

60/252,574

    12-Dec-2003    22-Nov-2001

03109096.1

         Pending    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxxx

NP

    22-Nov-2000

60/252,574

    20-May-2003    22-Nov-2001

156015

    10-May-2008

156015

      Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxxx

DIV

    24-Nov-2000

60/252,574

    20-Jul-2006    22-Nov-2001

176976

    1-Dec 2012

176976

   3182.021IL11    Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxx

NP

    22-Nov-2000

60/252,574

    22-May-2003    22-Nov-2001

796/CHENP/2003

    19-Sep-2008

223638

      Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

 

13

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxx

NP

    22-Nov-2000

60/252,574

    22-May-2003    22-Nov-2001

2,429,817

       3182.021CA01    Pending    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

26040

    Australia

NP

    22-Nov-2000

60/252,574

    23-May-2003    22-Nov-2001

0000000000

    21-Dec-2006

0000000000

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxx

NP

    22-Nov-2000

60/252,574

    23-May-2003    22-Nov-2001

2002-544008

    01-Aug-2008

4,162,486

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxx

DIV

    24-Nov-2000

60/252,574

    10-Jun-2008    22-Nov-2001

2008-151301

    25 May 2012

5001906

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxx

NP

    22-Nov-2000

60/252,574

    22-Jul-2003    22-Nov-2001

01822215.3

    06-Jan-2010

ZL01822215.3

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

26043

    Republic of Korea

NP

    22-Nov-2000

60/252,574

    24-May-2003    22-Nov-2001

2003-7006991

    17-Oct-2008

865142

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxxx

NP

    22-Nov-2000

60/252,574

    22-May-2003    22-Nov-2001

PA/a/2003/004517

    02-Sep-2009

269738

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

00000

    Xxxxxx

DIV

    24-Nov-2000

60/252,574

    12-Jun-2009    22-Nov-2001

MX/a/2009/006365

    2 December 2011

293020

    3182.021MX11    Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX Xxxxxx

 

14

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Xxxxxxxx

00000

    XXX

CIP

    17-Nov-2000

60/248,582

       30-Apr-2007

11/790,992

         Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

43177

    PCT    30-Apr-2007

11/790,992

       27-Apr-2008

IL2008/000543

    Publ. Date: 06-Nov-2008

Publ. #: WO2008/132729

      Expired    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART
Eyal; BANGIO Livnat;
XXXXX Xxxxxxx

47030

    Europe

NP

    30-Apr-2007

11/790,992

    27-Nov-2009    27-Apr-2008

08738245.3

         Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

48882

    Hong Kong

NP

    30-Apr-2007

11/790,992

    11-Jun-2010    27-Apr-2008

10105838.3

         Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

00000

    Xxxxx

NP

    30-Apr-2007

11/790,992

    30-Oct-2009    27-Apr-2008

2010-505002

         Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

00000

    Xxxxxx

NP

    30-Apr-2007

11/790,992

    27-Oct-2009    27-Apr-2008

2,685,394

         Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

00000

    Xxxxx

NP

    30-Apr-2007

11/790,992

    30-Dec-2009    27-Apr-2008

200880022935.2

      3182.039CN01    Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

 

15

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxxxxx

NP

    30-Apr-2007

11/790,992

    27-Nov-2009    27-Apr-2008

2008243817

          Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

47035

    Republic of Korea

NP

    30-Apr-2007

11/790,992

    18-Nov-2009    27-Apr-2008

2009-7024041

          Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

[* * *]

                        

00000

    Xxxxxx

NP

    30-Apr-2007

11/790,992

    26-Oct-2009    27-Apr-2008

201760

          Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

00000

    Xxxxxx

NP

    30-Apr-2007

11/790,992

    29-Oct-2009    27-Apr-2008

MX/a/2009/011750

          Pending    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

47039

    New Zealand

NP

    30-Apr-2007

11/790,992

    27-Nov-2009    27-Apr-2008

581511

    5 June 2012

581511

    3182.039NZ01    Granetd    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

47040

    South Africa

NP

    30-Apr-2007

11/790,992

    25-Nov-2009    27-Apr-2008

2009/08331

    29-Dec-2010

2009/08331

       Granted    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

00000

    Xxxxxxxxx

NP

    30-Apr-2007

11/790,992

    30-Oct-2009    27-Apr-2008

200907209-1

    15 May 2012

156740

    3182.039SG01    Granted    HARATS Dror;
XXXXXXXXXXX Xxxxxxxx;
BREITBART Eyal;
BANGIO Livnat; XXXXX
Xxxxxxx

 

16

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR DEFICIENT MICE

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

 

METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

01/23033

    PCT    04-Jan-2001

60/259,512

       03-Jan-2002

IL02/00005

    Publ. Date: 11-Jul-2002

Publ. #: WO02/053092

      Expired    HARATS Dror; XXXXXX
Xxxxx

00000

    Xxxxxx

NP

    04-Jan-2001

60/259,512

    03-Jul-2003    03-Jan-2002

156770

         Allowed    HARATS Dror; XXXXXX
Xxxxx

00000

    Xxxxx

NP

    04-Jan-2001

60/259,512

    04-Jul-2003    03-Jan-2002

1044/CHENP/2003

    19-Sep-2008

223640

      Granted    HARATS Dror; XXXXXX
Xxxxx

00000

    XXX

NP

    04-Jan-2001

60/259,512

    02-Jul-2003    03-Jan-2002

10/451,370

    09-Oct-2007

7,279,459

      Granted    HARATS Dror; XXXXXX
Xxxxx

26050

    Australia

NP

    04-Jan-2001

60/259,512

    11-Jul-2003    03-Jan-2002

2002225301

    03-Mar-2006

2002225301

      Granted    HARATS Dror; XXXXXX
Xxxxx

00000

    Xxxxx

NP

    04-Jan-2001

60/259,512

    03-Jul-2003    03-Jan-2002

2002-554043

    26-Sep-2008

4,191,997

      Granted    HARATS Dror; XXXXXX
Xxxxx

00000

    Xxxxx

NP

    04-Jan-2001

60/259,512

    04-Sep-2003    03-Jan-2002

02805950.6

         Pending    HARATS Dror; XXXXXX
Xxxxx

 

17

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxx

NP

    04-Jan-2001

60/259,512

    01-Jun-2003    03-Jan-2002

PA/a/2003/006043

    17-Mar-2009

265173

       Granted    HARATS Dror; XXXXXX
Xxxxx

26045

    Europe

NP

    04-Jan-2001

60/259,512

    18-Jul-2003    03-Jan-2002

02715682.7

          Abandoned    HARATS Dror; XXXXXX
Xxxxx

27463

    Hong Kong

NP

    04-Jan-2001

60/259,512

    28-Jan-2004    03-Jan-2002

04100565.1

          Abandoned    HARATS Dror; XXXXXX
Xxxxx

00000

    Xxxxxx

NP

    04-Jan-2001

60/259,512

    03-Jul-2003    03-Jan-2002

2,433,781

          Abandoned    HARATS Dror; XXXXXX
Xxxxx

[* * *]

                        

 

FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

[* * *]

                        
   PCT    Sept. 1, 2011

61/529,989

       Aug. 31, 2012

PCT/US2012/053533

       3182.013PC01    Pending    XXXX Xxxxxx; XXXXX Xxxxxx
M.; XxXXXXXXXX Xxxx;
XXXXXXX Xxx; XXXXXXXXX
Xxxxxxx

 

18

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		        Status    Xxxxxxxx

00000

    XXX

CIP

    17-Nov-2000

60/248,582

       23-Feb-2006

11/359,513

    18 October 2011

8,039,261

   3182.0380000    Granted    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
BANGIO Livnat; XXXXX Xxxxxxx

37180

    PCT    23-Feb-2006

11/359,513

       22-Feb-2007

IL2007/000242

    Publ. Date: 30-Aug-2007

Publ. #: WO2007/096882

      Expired    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; BANGIO Xxxxxx

00000

    XXX

NP

    17-Nov-2000

60/248,582

    20-Aug-2008    22-Feb-2007

12/224,178

         Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
BANGIO Livnat; XXXXX Xxxxxxx

44708

    Europe

NP

    23-Feb-2006

11/359,513

    28-Aug-2008    22-Feb-2007

07713267.8

         Pending    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; BANGIO Livnat

[* * *]

                       

00000

    Xxxxxx

NP

    23-Feb-2006

11/359,513

    19-Aug-2008    22-Feb-2007

193554

         Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; BANGIO Livnat

[* * *]

                       

00000

    Xxxxxx

NP

    23-Feb-2006

11/359,513

    20-Aug-2008    22-Feb-2007

2,638,829

         Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; BANGIO Livnat

 

19

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxxxxx

NP

    23-Feb-2006

11/359,513

    23-Sep-2008    22-Feb-2007

2007219088

          Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; XXXXXX Xxxxxx

00000

    Xxxxx

NP

    23-Feb-2006

11/359,513

    25-Aug-2008    22-Feb-2007

2008-555946

          Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; XXXXXX Xxxxxx

00000

    Xxxxx

NP

    23-Feb-2006

11/359,513

    21-Oct-2008    22-Feb-2007

200780014285.2

          Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; XXXXXX Xxxxxx

00000

    Xxxxxxxx of Korea

NP

    23-Feb-2006

11/359,513

    22-Sep-2008    22-Feb-2007

2008-7023144

          Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; XXXXXX Xxxxxx

00000

    Xxxxxx

NP

    23-Feb-2006

11/359,513

    22-Aug-2008    22-Feb-2007

MX/a/2008/010859

          Abandoned    HARATS Dror; XXXXXXXXXXX
Xxxxxxxx; BREITBART Eyal;
XXXXX Xxxxxxx; BANGIO Livnat

[* * *]

                        

[* * *]

                        

[* * *]

                        

 

PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Xxxxxxxx

00000

    XXX CIP    09-Jul-2004

60/586,219

       09-Jan-2007

11/650,973

    05-Oct-2010

7,807,847

    3182.0200001    Granted    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

49396

    USA DIV    09-Jul-2004

60/586,219

    24-Aug-2010    09-Jan-2007

12/861,921

    28-Feb 2012

8,124,800

    3182.0200002    Granted    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

 

20

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

52800

    USA DIV    09-Jul-2004

60/586,219

    May 24, 2012    January 26, 2012

13/358,573

       3182.0200003    Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI
   USA CIP    09-Jul-2004

60/586,219

       Nov. 9, 2012

13/672,811

       3182.0200004    Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI
   US CON    09-Jul-2004

60/586,219

       Dec. 10, 2012

13/709,198

       3182.0200005    Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI

 

IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent Xx.		   XXXX Xxx    Xxxxxx    Xxxxxxxx

00000

    PCT    09-Jan-2007

11/650,973

       02-Jan-2008

IL2008/000013

    Publ. Date: 17-Jul-2008

Publ. #: WO2008/084472

      Expired    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx Xxxxxx

NP

    09-Jan-2007

11/650,973

       02-Jan-2008

2009/05601

    26-May-2010

2009/05601

      Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxx Xxxxxxx

NP

    09-Jan-2007

11/650,973

    07-Aug-2009    02-Jan-2008

578947

    4-Dec 2011

578947

   3182.020NZ01    Granted    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxx Xxxxxxx

DIV

    09-Jan-2007

11/650,973

    15-Jun-2011    02-Jan-2008

593529

      3182.020NZ11    Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

[* * *]

                       

 

21

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

    Xxxxxxxxx

NP

    09-Jan-2007

11/650,973

    07-Aug-2009    02-Jan-2008

2008204238

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

NP

    09-Jan-2007

11/650,973

    09-Jul-2009    02-Jan-2008

MX/a/2009/007422

    9-Jan 2012

294470

       Granted    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

[* * *]

                        

00000

    Xxxxxx

NP

    09-Jan-2007

11/650,973

    09-Jul-2009    02-Jan-2008

199792

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx

NP

    09-Jan-2007

11/650,973

    31-Aug-2009    02-Jan-2008

200880006707.6

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxxxx xx Xxxxx

NP

    09-Jan-2007

11/650,973

    27-Jul-2009    02-Jan-2008

2009-7015780

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxx

NP

    09-Jan-2007

11/650,973

    09-Jul-2009    02-Jan-2008

2009-545295

          Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

00000

    Xxxxxx

NP

    09-Jan-2007

11/650,973

    06-Jul-2009    02-Jan-2008

2,674,902

          Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxxxx

NP

    09-Jan-2007

11/650,973

    07-Aug-2009    02-Jan-2008

08700247.3

          Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti
   Europe

Div

    09-Jan-2007

11/650,973

    July 27, 2012    02-Jan-2008

EP 12178298.1

       3182.020EP11    Pending    XXXXXXXX Xxxxxx;
XXXXXXXXXX-XXXXX Xxx

00000

    Xxxx Xxxx

XX

       16-Mar-2010    02-Jan-2008

10102729.2

          Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti

 

22

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

 

METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

50375

    PCT    05-Jan-2010

61/282,228

       05-Jan-2011

IL2011/000007

    Publ. Date: 14-Jul-2011

Publ. #: WO2011/083464

      Expired    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx
   US NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011      3182.0310002    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx
   EP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011      3182.031EP02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx
   IL    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011      3182.031IL02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx

[* * *]

                       
   JP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011      3182.031JP02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx

 

23

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

[* * *]

                        
   MX    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.031MX02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx

[* * *]

                        

[* * *]

                        

[* * *]

                        
   Canada    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.031CA02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx
   Au    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.031AU02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXX Xxxxxx; XXXXX
Xxxx; XXXXX Xxxx

 

COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       

50376

    PCT    05-Jan-2010

61/282,228

       05-Jan-2011

IL2011/000009

    Publ. Date: 14-Jul-2011

Publ. #: WO2011/083466

   3182.032PC02    Expired    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.

 

24

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

   US NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.0320002    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.
   EU NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032EP02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.
   IL NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032IL02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.

[* * *]

                        
   JP NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032JP02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.
   KR NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032KR02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.
   MX NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032MX02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.

[* * *]

                        

[* * *]

                        

[* * *]

                        
   CA NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032CA02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.
   AU NP    05-Jan-2010

61/282,228

    June 2012    05-Jan-2011       3182.032AU02    Pending    BREITBART Eyal; BANGIO
Livnat; XXXXX Xxxx;
XXXXXXX Xxxxxx J.

 

25

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		         Status    Xxxxxxxx

00000

    XXX

CIP

    27-May-2003

10/445,347

       28-Sep-2006

11/528,657

    01-Dec-2009

7,625,882

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX
Xxxxxx; KOVALEVSKI-
ISHAI Eti; XXXXX Xxxx;
XXXXXX Xxxxxx

00000

    XXX

DIV

    27-May-2003

10/445,347

    14-Oct-2009    28-Sep-2006

12/588,371

    05-Jul-2011

7,973,023

       Granted    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX
Xxxxxx; KOVALEVSKI-
ISHAI Eti; XXXXX Xxxx;
XXXXXX Xxxxxx

00000

    XXX

CON

    27-May-2003

10/445,347

    13-Apr-2011    28-Sep-2006

13/085,542

          Pending    HARATS Dror; XXXXXX
Xxxxx; XXXXXXXX
Xxxxxx; KOVALEVSKI-
ISHAI Eti; XXXXX Xxxx;
XXXXXX Xxxxxx

 

AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

00/21414

    Israel

Basic

          04-Oct-1998

126447

    30-Dec-2004

126447

       Granted    HARATS Dror; XXXXXXXXX
Xxxxxx; XXXXXX Xxxxx

 

26

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status   

Inventor

01/21558

    PCT    04-Oct-1998

126447

    01-Apr-2001    30-Sep-1999

IL99/00519

    Publ. Date: 13-Apr-2000

Publ. #: WO00/20019

      Expired   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21884

    Europe

NP

    04-Oct-1998

126447

       30-Sep-1999

99970026.3

    14-May-2003

1126867

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21886

    Canada

NP

    04-Oct-1998

126447

       30-Sep-1999

2,345,445

    24-Aug-2010

2,345,445

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21887

    Australia

NP

    04-Oct-1998

126447

       30-Sep-1999

59966/99

    28-Aug-2003

760582

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21888

    China

NP

    04-Oct-1998

126447

    04-Apr-2001    30-Sep-1999

99814030.9

    24-Nov-2004

ZL99814030.9

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

02/23904

    Hong Kong

NP

    04-Oct-1998

126447

    19-Jul-2002    30-Sep-1999

02105365.4

    18-Nov-2005

HK1043743

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

00000

    Xxxxx

DIV

    04-Oct-1998

126447

    23-Sep-2004    30-Sep-1999

200410011940.7

    05-Nov-2008

ZL200410011940.7

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

30562

    Hong Kong

DIV

    04-Oct-1998

126447

    28-Sep-2005    30-Sep-1999

05108561.7

    21-Aug-2009

HK1076600

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21889

    Singapore

NP

    04-Oct-1998

126447

       30-Sep-1999

200101998-3

    30-Apr-2003

80182

      Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

 

27

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00/00000

    Xxxxx

NP

    04-Oct-1998

126447

       30-Sep-1999

2000-573378

          Pending   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21891

    Hungary

NP

    04-Oct-1998

126447

    30-Sep-1999    30-Sep-1999

P0104410

          Pending   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

[* * *]

                        

00/00000

    Xxxxxxxx xx Xxxxx

NP

    04-Oct-1998

126447

       30-Sep-1999

2001-7004285

    02-Feb-2007

680707

       Granted   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/21885

    USA

NP

    04-Oct-1998

126447

    30-Mar-2001    30-Sep-1999

09/806,400

          Abandoned   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

01/22498

    USA

CON

    04-Oct-1998

126447

    04-Sep-2001    30-Sep-1999

09/944,592

          Abandoned   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx

 

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status   

Xxxxxxxx

00000

    XXX

CIP

    04-Oct-1998

126447

       15-Apr-2005

11/106,665

          Abandoned   

HARATS Dror; XXXXXXXXX

Xxxxxx; XXXXXX Xxxxx;

XXXXX Xxxx

 

28

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

    Country    Earliest
      Priority      		          Entry Date          Filing Date
  Application No.  		    Issue Date
    Patent No.    		    SKGF Ref    Status   

Xxxxxxxx

00000

    XXX

CIP

    22-Nov-2000

60/252,574

       27-May-2003

10/445,347

    04-Jan-2005

6,838,452

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti; XXXXX Xxxx

00000

    XXX

DIV

    24-Nov-2000

60/252,574

    24-Nov-2003    27-May-2003

10/718,596

    06-Mar-2007

7,186,704

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

    XXX

DIV

    24-Nov-2000

60/252,574

    19-Jul-2005    27-May-2003

11/183,884

    17-Mar-2009

7,504,388

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

    XXX

DIV

    24-Nov-2000

60/252,574

    17-Feb-2009    27-May-2003

12/371,930

    22-Feb-2011

7,893,291

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

    XXX

CON

    24-Nov-2000

60/252,574

    06-Jan-2011    27-May-2003

12/985,365

    17 April
2012

8,158,611

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

53355

    USA

CON

    24-Nov-2000

60/252,574

    March 27, 2012    27-May-2003

13/431,262

          Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

 

29

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 

OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

 

Our Ref

   Country        Earliest Priority              Entry Date          Filing Date
  Application No.  		    Issue Date
    Patent Xx.    		   XXXX Xxx    Xxxxxx   

Xxxxxxxx

00000

   PCT    27-May-2003

10/445,347

       27-May-2004

IL2004/000453

    Publ. Date: 09-Dec-2004

Publ. #: WO2004/106486

      Expired   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx

00000

   XXX

NP

    27-May-2003

10/445,347

    25-Apr-2008    27-May-2004

10/567,543

    08-Mar-2011

7,902,176

      Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

   Xxxxxx

NP

    27-May-2003

10/445,347

    25-Nov-2005    27-May-2004

pa/A/2005/012784

    14-Oct-2008

261341

      Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx

[* * *]

                      

30947

   Europe

NP

    27-May-2003

10/445,347

    07-Dec-2005    27-May-2004

04735088.9

         Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

32340

   Hong Kong

NP

    27-May-2003

10/445,347

    03-Aug-2006    27-May-2004

06108608.1

         Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

   Xxxxx

NP

    27-May-2003

10/445,347

    30-Nov-2005    27-May-2004

2006-531006

         Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

[* * *]

                      

00000

   Xxxxxx

NP

    27-May-2003

10/445,347

    28-Nov-2005    27-May-2004

2,527,483

         Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

   Xxxxx

NP

    27-May-2003

10/445,347

    01-Nov-2005    27-May-2004

200480021217.5

    22-Dec-2010

ZL200480021217.5

      Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

 

30

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

   Xxxxx

DIV

    27-May-2003

10/445,347

    25-Oct-2010    27-May-2004

201010537971.1

          Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

30951

   Australia

NP

    27-May-2003

10/445,347

    13-Dec-2005    27-May-2004

2004243695

    17-Mar-2011

2004243695

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

30952

   Republic of Korea

NP

    27-May-2003

10/445,347

    28-Nov-2005    27-May-2004

2005-7022741

    3-Nov 2011

1081977

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

50809

   Republic of Korea

DIV

    27-May-2003

10/445,347

    18-Feb-2011    27-May-2004

2011-7003840

    23 Feb 2012

00-0000000

       Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

30953

   New Zealand

NP

    27-May-2003

10/445,347

    01-Dec-2005    27-May-2004

544285

    12-Mar-2009

544285

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

30954

   South Africa

NP

    27-May-2003

10/445,347

    01-Dec-2005    27-May-2004

2005/09929

    27-Dec-2006

2005/9929

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

00000

   Xxxxx

NP

    27-May-2003

10/445,347

    27-Dec-2005    27-May-2004

3555/CHENP/2005

    26-Mar-2009

232654

       Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

[* * *]

                       

 

31

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

[* * *]

                      

30957

   Russian Federation

NP

    27-May-2003

10/445,347

    01-Dec-2005    27-May-2004

2005140666

    27-Jul-2009

2362567

      Granted   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

46052

   Russian Federation

DIV

    27-May-2003

10/445,347

    06-Apr-2009    27-May-2004

2009112686

         Pending   

HARATS Dror; XXXXXX

Xxxxx; XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

XXXXX Xxxx

 

OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF

 

Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status   

Inventor

[* * *]

                      

46530

   PCT    08-Oct-2008

61/103,571

       01-Oct-2009

IL2009/000949

    Publ. Date: 15-Apr-2010

Publ. #: WO2010/041242

      Expired   

XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; XXXXXX

Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx

50053

   USA

NP

    08-Oct-2008

61/103,571

    06-Apr-2011    01-Oct-2009

13/122,766

         Pending   

XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; XXXXXX

Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx

50054

   Europe

NP

    08-Oct-2008

61/103,571

    20-Apr-2011    01-Oct-2009

09818874.1

         Pending   

XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; XXXXXX

Xxxxxx; XXXXXX Xxxx; XXXXX Xxxx

 

32

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

00000

   Xxxxxx

NP

    08-Oct-2008

61/103,571

    05-Apr-2011    01-Oct-2009

212153

         Pending   

XXXXXXXX Xxxxxx;

KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; XXXXXX

Xxxxxx; XXXXXX Xxxx; XXXXX

Xxxx

 

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

 

Our Ref

   Country          Earliest Priority                Entry Date          Filing Date
  Application No.  		    Issue Date
    Patent No.    		   SKGF Ref    Status   

Inventor

[* * *]

                      

31865

   PCT    15-Apr-2005

60/671,500

       11-Apr-2006

IL2006/000467

    Publ. Date: 19-Oct-2006

Publ. #: WO2006/109312

      Expired   

XXXXX Xxxx; BREITBART

Eyal

41853

   Europe

NP

    15-Apr-2005

60/671,500

    24-Oct-2007    11-Apr-2006

06728268.1

         Abandoned   

XXXXX Xxxx; BREITBART

Eyal

41854

   USA

NP

    15-Apr-2005

60/671,500

    10-Oct-2007    11-Apr-2006

11/918,141

         Abandoned   

XXXXX Xxxx; BREITBART

Eyal

[* * *]

                      

[* * *]

                      

NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS

 

33

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       
OXIDIZED LIPID COMPOUNDS AND USES THEREOF

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent Xx.		   XXXX Xxx    Xxxxxx    Xxxxxxxx

00000

    PCT    06-Nov-2008

61/193,220

       05-Nov-2009

IL2009/001049

    Publ. Date: 14-May-2010

Publ. #: WO2010/052718

      Expired    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti;
XXXXX Xxxx;
BREITBART Eyal;
XXXXXX Xxxxxx; XXXXXX
Xxxx; XXXXX Xxxx

50603

    USA

NP

    06-Nov-2008

61/193,220

    05-May-2011    05-Nov-2009

13/127,717

         Pending    XXXXXXXX Xxxxxx;
KOVALEVSKI-ISHAI Eti;
XXXXX Xxxx;
BREITBART Eyal;
XXXXXX Xxxxxx; ZINIUK
Zeev; FEIGE Erez

[* * *]

                       

50605

    Europe

NP

    06-Nov-2008

61/193,220

    16-May-2011    05-Nov-2009

09824498.1

         Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

51983

    Hong Kong

NP

          05-Nov-2009         Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

 

34

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

50606

    Canada

NP

    06-Nov-2008

61/193,220

    13-Apr-2011    05-Nov-2009

2,740,726

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

[* * *]

                        

50608

    Australia

NP

    06-Nov-2008

61/193,220

    15-Apr-2011    05-Nov-2009

2009312355

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

50609

    New Zealand

NP

    06-Nov-2008

61/193,220

    19-Apr-2011    05-Nov-2009

592357

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

[* * *]

                        

50611

    Japan

NP

    06-Nov-2008

61/193,220

    06-May-2011    05-Nov-2009          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

50612

    Republic of Korea

NP

    06-Nov-2008

61/193,220

    02-Jun-2011    05-Nov-2009

2011-7012700

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

 

35

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

50613

    Mexico

NP

    06-Nov-2008

61/193,220

    04-May-2011    05-Nov-2009

MX/a/2011/004773

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

50614

    Russian Federation

NP

    06-Nov-2008

61/193,220

    06-Jun-2011    05-Nov-2009

2011122729

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

50615

    China

NP

    06-Nov-2008

61/193,220

    30-Jun-2011    05-Nov-2009

200980153378.2

          Pending    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC PROMOTER

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		   

Issue Date

Patent No.

    SKGF Ref    Status    Inventor

[* * *]

                        
POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		   

Issue Date

Patent No.

    SKGF Ref    Status    Inventor

02/23346

    PCT    19-Oct-2001

60/330,118

       01-May-2002

IL02/00339

   

Publ. Date: 24-Apr-2003

Publ. #: WO03/033514

       Expired    HARATS Dror;
GREENBERGER Shoshana

27526

    USA

NP

    19-Oct-2001

60/330,118

    12-Apr-2004    01-May-2002

10/490,746

   

08-Sep-2009

7,585,666

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

 

36

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

44506

    USA

DIV

    19-Oct-2001

60/330,118

    08-Aug-2008    01-May-2002

12/222,439

   

02-Aug-2011

7,989,427

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

51506

    USA

DIV

    19-Oct-2001

60/330,118

    20-Jun-2011    01-May-2002

13/163,767

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27527

    Europe

NP

    19-Oct-2001

60/330,118

    21-Apr-2004    01-May-2002

02801473.6

   

22-Sep-2010

1436313

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

29028

    Hong Kong

NP

    19-Oct-2001

60/330,118

    06-Jan-2005    01-May-2002

05100081.5

   

01-Apr-2011

HK1067641

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

49785

    Europe

DIV

    19-Oct-2001

60/330,118

    17-Sep-2010    01-May-2002

EP10177257.2

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

47553

    Europe

DIV

    19-Oct-2001

60/330,118

    18-Nov-2009    01-May-2002

09176343.3

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

49931

    Hong Kong

DIV

    19-Oct-2001

60/330,118

    10-Dec-2010    01-May-2002

10111522.2

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

51004

    Hong Kong

DIV

    19-Oct-2001

60/330,118

    27-Apr-2011    01-May-2002

11104228.3

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27528

    Japan

NP

    19-Oct-2001

60/330,118

    16-Apr-2004    01-May-2002

2003-536253

   

22-Aug-2008

4,173,446

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

 

37

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

27529

    Republic of Korea

NP

    19-Oct-2001

60/330,118

    17-Apr-2004    01-May-2002

2004-7005720

   

24-Oct-2008

866117

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27530

    India

NP

    19-Oct-2001

60/330,118

    19-Apr-2004    01-May-2002

801/CHENP/2004

   

26-Dec-2008

226357

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27531

    China

NP

    19-Oct-2001

60/330,118

    09-Jun-2004    01-May-2002

02824547.4

   

01-Jul-2009

ZL02824547.4

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

46077

    China

DIV

    19-Oct-2001

60/330,118

    27-Apr-2009    01-May-2002

200910137707.6

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27532

    Singapore

NP

    19-Oct-2001

60/330,118

    16-Apr-2004    01-May-2002

200402237-2

   

31-May-2006

103725

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27533

    Canada

NP

    19-Oct-2001

60/330,118

    16-Apr-2004    01-May-2002

2,463,816

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27534

    Mexico

NP

    19-Oct-2001

60/330,118

    19-Apr-2004    01-May-2002

PA/a/2004/003514

   

12-Nov-2010

280956

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

[* * *]

                        

27535

    Australia

NP

    19-Oct-2001

60/330,118

    20-Apr-2004    01-May-2002

2002307793

   

17-May-2007

2002307793

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27536

    New Zealand

NP

    19-Oct-2001

60/330,118

    16-Apr-2004    01-May-2002

532348

   

12-Oct-2006

532348

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

27537

    South Africa

NP

    19-Oct-2001

60/330,118

    08-Apr-2004    01-May-2002

2004/2756

   

31-May-2006

2004/02756

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

 

38

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN CARDIOVASCULAR, CANCER AND WOUND HEALING

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

[* * *]

                       
                      

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		   SKGF Ref    Status    Inventor

01/22752

    PCT    17-Nov-2000

60/248,582

       15-Nov-2001

IL01/01059

    Publ. Date: 23-May-2002

Publ. #: WO02/40629

      Expired    HARATS Dror

26025

    Europe

NP

    17-Nov-2000

60/248,582

    15-May-2003    15-Nov-2001

01996590.4

    20-Jan-2010

1443970

      Granted    HARATS Dror; BLOOM Nira

29027

    Hong Kong

NP

    17-Nov-2000

60/248,582

    12-Jan-2005    15-Nov-2001

05100240.3

    20-Aug-2010

HK1068057

      Granted    HARATS Dror; BLOOM Nira

47088

    Europe

DIV

    17-Nov-2000

60/248,582

    04-Nov-2009    15-Nov-2001

09174998.6

         Pending    HARATS Dror; BLOOM Nira

49806

    Europe

DIV

    17-Nov-2000

60/248,582

    01-Oct-2010    15-Nov-2001

EP10185193.9

         Pending    HARATS Dror; BLOOM Nira

49498

    Hong Kong

DIV

    17-Nov-2000

60/248,582

    13-Oct-2010    15-Nov-2001

10109698.4

         Pending    HARATS Dror; BLOOM Nira

 

39

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

52630

    Hong Kong

DIV

    17-Nov-2000

60/248,582

    2-Dec-2011    15-Nov-2001

11113094.5

       3182.034HK21    Pending    HARATS Dror; BLOOM Nira

26026

    Israel

NP

    17-Nov-2000

60/248,582

    15-May-2003    15-Nov-2001

155940

    30-Mar-2009

155940

       Granted    HARATS Dror; BLOOM Nira

26027

    India

NP

    17-Nov-2000

60/248,582

    14-May-2003    15-Nov-2001

743/CHENP/2003

    20-Nov-2007

211599

       Granted    HARATS Dror; BLOOM Nira

26028

    USA

NP

    17-Nov-2000

60/248,582

    16-May-2003    15-Nov-2001

10/416,917

          Abandoned    HARATS Dror

26029

    Canada

NP

    17-Nov-2000

60/248,582

    15-May-2003    15-Nov-2001

2,429,342

          Pending    HARATS Dror; BLOOM Nira

26030

    Australia

NP

    17-Nov-2000

60/248,582

    15-May-2003    15-Nov-2001

2002224002

    26-Jul-2007

2002224002

       Abandoned    HARATS Dror

28653

    Australia

DIV

    17-Nov-2000

60/248,582

    01-Dec-2004    15-Nov-2001

2003222427

    09-Sep-2010

2003222427

       Granted    HARATS Dror; BREITBART
Eyal; BLOOM Nira

49098

    Australia

DIV

    15-Nov-2001

2002224002

    25-Jun-2010    15-Nov-2001

2010202660

    1-Dec 2011

2010202660

       Granted    HARATS Dror; BREITBART
Eyal; BLOOM Nira

26031

    Japan

NP

    17-Nov-2000

60/248,582

    16-May-2003    15-Nov-2001

2002-543626

    16-Jan-2009

4,243,653

       Granted    HARATS Dror; BLOOM Nira

26032

    China

NP

    17-Nov-2000

60/248,582

    16-Jul-2003    15-Nov-2001

01822075.4

    04-Feb-2009

ZL0182275.4

       Granted    HARATS Dror; BLOOM Nira

 

40

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

26033

    Republic of Korea

NP

    17-Nov-2000

60/248,582

    17-May-2003    15-Nov-2001

2003-7006728

    14-Nov-2008

869814

    Granted    HARATS Dror

44105

    Republic of Korea

DIV

    17-Nov-2000

60/248,582

    28-Jul-2008    15-Nov-2001

2008-7018598

    10-Sep-2009

917854

    Granted    HARATS Dror;  BLOOM Nira

26034

    Mexico

NP

    17-Nov-2000

60/248,582

    16-May-2003    15-Nov-2001

PA/a/2003/004325

    15-Aug-2008

259670

    Granted    HARATS Dror

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

 

Our Ref

   

Country

    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status   

Inventor

28918

   

USA

CIP

    04-Oct-1998

126447

       17-Nov-2004

10/989,724

          Abandoned    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

 

Our Ref

   

Country

    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status   

Inventor

30236

    PCT    17-Nov-2004

10/989,724

       25-Sep-2005

IL2005/001022

    Publ. Date:

26-May-2006

Publ. #: |WO2006/054281

       Expired   

HARATS Dror;

SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

39233

   

Europe

NP

    17-Nov-2004

10/989,724

    13-Jun-2007    25-Sep-2005

05788473.6

          Abandoned   

HARATS Dror;

SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

42004

   

Hong Kong

NP

    17-Nov-2004

10/989,724

       12-Sep-2007

07109873.6

          Abandoned   

HARATS Dror;

SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

 

41

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

28376

    USA

CIP

    17-Nov-2000

60/248,582

       14-Nov-2004

10/988,487

    6-Dec 2011

8,071,740

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

50225

    USA

DIV

    17-Nov-2000

60/248,582

    01-Feb-2011    14-Nov-2004

13/018,447

    26-June 2012

8,206,743

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

50927

    USA

DIV

    17-Nov-2000

60/248,582

    02-May-2011    14-Nov-2004

13/098,512

          Aban    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

47407

    USA

DIV

    17-Nov-2000

60/248,582

    13-Nov-2009    14-Nov-2004

12/591,252

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

60001

    USA

Con

    17-Nov-2000

60/248,582

    13-July 2012    14-Nov-2004

13/549,355

       3182.0370004    Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

30269

    PCT    14-Nov-2004       14-Nov-2005    Publ. Date: 18-May-2006       Expired    HARATS Dror;
GREENBERGER Shoshana

 

42

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

      10/988,487       IL2005/001195    Publ. #: WO2006/051545     

[* * *]

                    

[* * *]

                    

47087

    Europe

DIV

    14-Nov-2004

10/988,487

    28-Aug-2009    14-Nov-2005

09168899.4

    2 Nov 2011

2174668

   Grnated    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

49224

    Hong Kong

DIV

       12-Oct-2010    14-Nov-2005

10109638.7

    15 June 2012

HK1143078

   Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

49804

    Europe

DIV

    14-Nov-2004

10/988,487

    01-Oct-2010    14-Nov-2005

EP10185195.4

    26 Sep 2012

2301586

   Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

49805

    Europe

DIV

    14-Nov-2004

10/988,487

    30-Sep-2010    14-Nov-2005

EP10184033.8

      Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39318

    Australia

NP

    14-Nov-2004

10/988,487

    08-Jun-2007    14-Nov-2005

2005303385

      Allowed    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

51825

    Australia

DIV

    14-Nov-2004

10/988,487

       14-Nov-2005    28 June 2012

2011205076

   Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

53691

    Australia    14-Nov-2004    15 June 2012    14-Nov-2005      Pending    HARATS Dror;
GREENBERGER Shoshana;

 

43

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

   DIV    10/988,487       2012203578          BREITBART Eyal; BANGIO
Livnat; PELED Michael

39323

    New Zealand

NP

    14-Nov-2004

10/988,487

    05-Jun-2007    14-Nov-2005

555612

    08-Apr-2010

555612

    Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

47297

    New Zealand

DIV

    14-Nov-2004

10/988,487

    09-Oct-2009    14-Nov-2005

580289

    05-Apr-2011

580289

    Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39324

    South Africa

NP

    14-Nov-2004

10/988,487

    05-Jun-2007    14-Nov-2005

2007/04687

    31-Dec-2008

2007/04687

    Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat

[* * *]

                     

50629

    Singapore

DIV

    14-Nov-2004

10/988,487

    11-Apr-2011    14-Nov-2005

201102612-7

       Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat

39315

    Israel

NP

    14-Nov-2004

10/988,487

    14-May-2007    14-Nov-2005

183187

       Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

50104

    Israel

DIV

    14-Nov-2004

10/988,487

    31-Oct-2010    14-Nov-2005

209034

       Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat

[* * *]

                     

[* * *]

                     

 

44

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

39317

    Canada

NP

    14-Nov-2004

10/988,487

    17-May-2007    14-Nov-2005

2,587,469

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39319

    Japan

NP

    14-Nov-2004

10/988,487

    14-May-2007    14-Nov-2005

2007-540833

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

52137

    Japan

Div

    14-Nov-2004

10/988,487

    Sep 2011    14-Nov-2005

2011-191492

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39320

    China

NP

    14-Nov-2004

10/988,487

    13-Aug-2007    14-Nov-2005

200580046412.8

          Aban    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39321

    Republic
of Korea

NP

    14-Nov-2004

10/988,487

    14-Jun-2007    14-Nov-2005

2007-7013464

          Pending    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael

39322

    Mexico

NP

    14-Nov-2004

10/988,487

    11-May-2007    14-Nov-2005

MX/a/2007/005783

    8 May 2012

299008

       Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat

52598

    Mexico

Div

    14-Nov-2004

10/988,487

       14-Nov-2005    4 Sep 2012

303042

    3182.037MX11    Granted    HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat

[* * *]

                        

 

45

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Method for treating vascular inflammation and psoriasis

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

[* * *]

                        

[* * *]

                        

 

Treatment Of Inflammation

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

[* * *]

                        

53305

    PCT    12 Dec 2011

61/569,545 and

12 Dec 2011

61/569,481

       11 Dec 2012

PCT/US2012/068995

       3182.014PC01    Pending    MENDEL, Itzhak;

FEIGE, Erez;

YACOV, Niva;

PROPHETE-MEIRAN, Oshrat;
BREITBART, Eyal;

SALEM, Yaniv

 

46

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Treatment Methods Using Adenovirus

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

[* * *]

                        

 

TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS

 

Our
Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		    SKGF Ref    Status    Inventor

N/A

    USA CIP    03-Mar-1994

08/254,015

       28-Feb-1995

08395742

    05-May-1998

5747340

    Originally assinged to Syntex
USA. Licensed to VBL		    Granted    HARATS Dror;

KURIHARA Hiroki;

NANETTE BELLONI Paula; SIGAL
Charles Elliott

 

METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS

 

Our Ref

    Country    Earliest Priority    Entry Date    Filing Date
Application No.		    Issue Date
Patent No.		  

SKGF Ref

    Status    Inventor

N/A

    PCT    08-Dec-2009

61/283,696

       07-Dec-2010

US2010/059204

    Publ. Date: 16-Jun-2011

Publ. #: WO/2011/071859

   As of June 2012, the applicant is also VBL    Pending    KOLESNICK, Richard, N.

STANCEVIC, Branka;

SADELAIN, Michel;

FUKS, Zvi;

VARDA-BLOOM, Nira;

HARATS, Dror;

 

47

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Trademark: VBL therapeutics & logo

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

47638

    Europe   5, 42 & 44       03-Dec-2009

008730541

    02-Jun-2010

008730541

       Registered

 

Trademark: VASCULAR BIOGENICS

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

42092

    Israel   42       23-Aug-2007

203346

    06-May-2009

203346

       Registered

43074

    USA

(Paris)

   42    23-Aug-2007

203346

    14-Feb-2008

77/397,305

    22-Jun-2010

3,805,239

       Registered

43075

    Europe

(Paris)

   5, 42 & 44    23-Aug-2007

203346

    18-Feb-2008

006675599

    20-Feb-2009

006675599

       Registered

 

48

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Trademark: VBL VASCULAR BIOGENICS LTD. & Device

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

42199

    Israel   42       09-Sep-2007

203748

    10-May-2009

203748

       Registered

43602

    USA

(Paris)

   42    09-Sep-2007

203748

    03-Mar-2008

77/411,204

    22-Jun-2010

3,805,245

       Registered

43603

    Europe

(Paris)

   42    09-Sep-2007

203748

    04-Mar-2008

006721823

    04-Sep-2009

006721823

       Registered

 

Trademark: VTS

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

42198

    Israel   5       09-Sep-2007

203747

    06-May-2009

203747

       Registered

43600

    USA

(Paris)

   5    09-Sep-2007

203747

    03-Mar-2008

77/411,151

    20-Oct-2009

3,697,519

       Registered

43601

    Europe

(Paris)

   5    09-Sep-2007

203747

    04-Mar-2008

006721484

    20-Feb-2009

006721484

       Registered

 

49

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Trademark: VASCULAR TARGETING SYSTEM VTS

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

41864

    Israel   5       23-Aug-2007

203345

    08-Sep-2009

203345

       Registered

43072

    USA

(Paris)

   5    23-Aug-2007

203345

    14-Feb-2008

77/397,328

    18-May-2010

3,789,108

       Registered

43073

    Europe

(Paris)

   5, 42 & 44    23-Aug-2007

203345

    18-Feb-2008

006675896

    29-Jan-2009

006675896

       Registered

 

50

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Trademark: VBL

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

42093

    Israel   42       23-Aug-2007

203347

    22-Jan-2009

203347

       Registered

43076

    USA

(Paris)

   42    23-Aug-2007

203347

    14-Feb-2008

77/397,293

    14-Jul-2009

3,653,176

       Registered

43077

    Europe

(Paris)

   5, 42 & 44    23-Aug-2007

203347

    18-Feb-2008

006673263

    22-Jan-2009

006673263

       Registered

 

Trademark: VBL therapeutics & logo

 

Our Ref

Client Ref

    Country   Class    Earliest
Priority		    Filing Date
Application No.		    Registration Date
Registration No.		    SKGF Ref    Status

47612

    Israel   42       30-Nov-2009

225329

    07-Feb-2011

225329

       Registered

47639

    USA

(Paris)

   42    30-Nov-2009

225329

    26-Apr-2010

85/023,397

    24-May-2011

3,964,829

       Registered

 

51

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Domains: VBL

xxxxxxxxxxxxxxxxx.xxx

xxxxxxxxxxxxxxxxxxxx.xxx

xxx-xxxxxxxxxxxx.xxx

xxxxxxxxxxxxxxx.xxx

xxxxx.xxx

xxxxxxxxxxxxxxxxx.xxx

xxx.xx.xx

xxxxx.xxx

xxxxxxxx-xxxxxxxxx.xxx

 

52

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].
AutoNDA by SimpleDocs

Document Metadata

Filed: June 6th, 2014
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!